Tetra Bio-Pharma Inc. (TBP), announced the positive results from an artificial intelligence study of Onternabez combined with Favipiravir Onternabez helps mitigate the response in various targets of inflammatory conditions, and Favipiravir acts against different SARS-CoV-2 targetsThese therapies against SARS-COV-2 created a new therapeutic that is expected to increase treatment efficacy and reduce the duration of the diseaseThe study also demonstrated that candidate ARDS-003, containing Onternabez, worked against various ARDS and Sepsis targetsTetra Bio-Pharma Inc. (TBP) is up 40.00 per cent and is trading at $0.03 per share as of 1:14 p.m. EST
Cannabinoid drug developer, Tetra Bio-Pharma (TBP), announced positive results from an artificial intelligence study.
The company studied the efficacy of Onternabez combined with Favipiravir against acute respiratory distress syndrome (ARDS), Sepsis, and COVID-19.
Onternabez helps mitigate the response in various targets of inflammatory conditions, and Favipiravir acts against different SARS-CoV-2 targets. The interaction between Favipiravir and Onternabez against SARS-COV-2 created a new therapeutic that is expected to increase treatment efficacy and reduce the duration of the disease.
Tetra shared that the study demonstrated its candidate ARDS-003, which contained the pharmaceutical ingredient Onternabez, worked against various ARDS and Sepsis targets.
Tetra’s scientific approach has enabled them to develop a pipeline of other cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.
The company has been working alongside Cellvera, a biopharmaceutical company that focuses on the commercial development of orally available nucleotide prodrugs.
Dr. Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented,
“This underscores our commitment with Cellvera to developing an innovative combination drug candidate to combat viral diseases… with Cellvera and the possibility of delivering the next scientific breakthroughs.”
Tetra Bio-Pharma Inc. (TBP) is up 40.00 per cent and is trading at $0.03 per share as of 1:14 p.m. EST.
The post Tetra Bio-Pharma (TSX:TBP) AI study shows drug efficacy appeared first on The Market Herald.
Powered by WPeMatico